The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism

Thromb Res. 2000 Aug 1;99(3):223-30. doi: 10.1016/s0049-3848(00)00236-x.

Abstract

To determine whether or not the PAI-1 4G/5G and t-PA I/D polymorphisms in African-Americans were linked to cardiovascular disease, the association of these polymorphisms to disease expression was analyzed in a recently completed case-control study of myocardial infarction or venous thromboembolism among African-Americans. All African-Americans patients with a history of venous thromboembolism attending an anticoagulant clinic, and patients with a history of a MI attending a cardiology clinic at a large local urban public hospital were eligible for inclusion as cases in the study. In this study it was observed that there was a statistically significant association between the D allele of the t-PA I/D polymorphism and venous thromboembolism and a nonsignificant association between the D allele and myocardial infarction among African-Americans. t-PA antigen levels were statistically significantly higher among both myocardial infarction and venous thromboembolism cases compared with control subjects. The genotypes were unrelated to t-PA plasma levels. There was no association between either myocardial infarction or venous thromboembolism and the 4G/5G PAI-1 genotype. It was also found that genotype frequencies for both PAI-1 4G/5G and t-PA I/D polymorphisms in African-American adults were different from those reported for both U.S. Causcians and Europeans.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Black People / genetics*
  • Black or African American*
  • Case-Control Studies
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Georgia / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / ethnology*
  • Myocardial Infarction / genetics
  • Odds Ratio
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic / genetics*
  • Risk
  • Tissue Plasminogen Activator / genetics*
  • Venous Thrombosis / ethnology*
  • Venous Thrombosis / genetics

Substances

  • Plasminogen Activator Inhibitor 1
  • Tissue Plasminogen Activator